Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.34 |
| ▸ | LYN | P07948 | 15/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.30 |
| ▸ | FRK | P42685 | 1/20 | 0.30 |
| ▸ | BLK | P51451 | 1/20 | 0.30 |
| ▸ | BMX | P51813 | 1/20 | 0.30 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.30 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31335633 | 0.88 | ABCG2 (0.33) | BTKLYNEGFRLCKSRC | |
| SCHEMBL31335870 | 0.86 | SPR (0.35) | BTKLYNEGFRLCKSRC | |
| SCHEMBL31335822 | 0.85 | TRAP1 (0.36) | BTKLYNSPR | |
| SCHEMBL31335592 | 0.85 | BTK (0.36) | BTKLYNEGFRLCKSRC | |
| SCHEMBL31335643 | 0.82 | LYN (0.33) | BTKLYN | |
| SCHEMBL31335585 | 0.81 | SPR (0.36) | BTKLYNSPR | |
| SCHEMBL31335713 | 0.81 | TRAP1 (0.37) | BTKLYNSPR | |
| SCHEMBL31335691 | 0.80 | TRAP1 (0.33) | BTKLYNSPR | |
| SCHEMBL31335646 | 0.76 | SPR (0.43) | BTKLYNSPR | |
| SCHEMBL25267660 | 0.76 | TRAP1 (0.36) | BTKLYNSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | claimed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | disclosed |